EPISODE · Aug 1, 2022 · 3 MIN
FDA D.I.S.C.O. Burst Edition: FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor
from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) · host U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Listen to a soundcast of the July 14, 2022 FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor.
Embed this episode
NOW PLAYING
FDA D.I.S.C.O. Burst Edition: FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor
0:00
3:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)?
This episode is 3 minutes long.
When was this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode published?
This episode was published on August 1, 2022.
Can I download this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!